Epanova® for Lowering Very High Triglycerides

Phase 2

Completed

• Conditions: Severe Hypertriglyceridemia
• Interventions: Drug: placebo; Drug: omefas

• Registration Number: NCT01242527
• Lead Sponsor: AstraZeneca

Brief Summary

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-11-15
• Study First Submitted QC: 2010-11-15
• Study First Posted: 2010-11-17
• Study Start: 2011-01
• Primary Completion: 2012-03
• Study Completion: 2012-04
• Results First Submitted: 2013-06-26
• Results First Submitted QC: 2013-06-27
• Results First Posted: 2013-09-06
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-24
• Last Update Posted: 2016-08-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 399

Inclusion Criteria

• Men or women, >=18 years of age.
• Very high serum TG values in the range >=500 mg/dL and <2000 mg/dL (>=5.65 mmol/L and <22.60 mmol/L)

Exclusion Criteria

• Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish.
• Known lipoprotein lipase impairment or deficiency or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.
• Unable to discontinue use of omega-3 drugs/supplements.
• Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism.
• Women who are pregnant, lactating, or planning to become pregnant. Women of childbearing potential who are not using acceptable contraceptive methods.
• Use of tamoxifen, estrogens or progestins that has not been stable for >4 weeks prior to Visit 1.
• Use of oral or injected corticosteroids or anabolic steroids.
• History of pancreatitis.
• History of symptomatic gallstone disease, unless treated with cholecystectomy.
• Uncontrolled diabetes.
• Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH).
• History of cancer (other than basal cell carcinoma) in the past 2 years.
• Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within six months prior to Visit 1.
• Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).
• Presence of an aortic aneurysm or resection of an aortic aneurysm within six months prior to Visit 1.
• Recent history (within six months prior to Visit 1) or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
• Poorly controlled hypertension.
• Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), glucose, glomerular filtration rate (GFR), platelet count,or hemoglobin outside of study range.
• Recent history (past 12 months) of drug abuse or alcohol abuse.
• Exposure to any investigational product, within 4 weeks prior to Visit 1.
• Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	-
Epanova 3 g	omefas	-
Epanova 4 g	omefas	-
Epanova 2 g	omefas	-

Primary Outcome Measures

Name	Time	Method
Fasting Serum Triglycerides	12 weeks	The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in triglycerides between placebo and the 2g/day, 3g/day and 4g/day Epanova groups